Site and mechanism of leptin action in a rodent form of congenital lipodystrophy
J. Clin. Invest. Esra Asilmaz, et al. 113:414 doi:10.1172/JCI19511 [Go to this article.]

Figure 5
Correction of fatty liver but not diabetes in ab^J/ab^J;aP2-nSREBP-1c transgenic mice. (a) Gross liver appearance in ab^J/ab^J;aP2-nSREBP-1c transgenic mice, aP2-nSREBP-1c transgenic mice, and WT mice. (b) Representative liver sections from aP2-nSREBP-1c and ab^J/ab^J;aP2-nSREBP-1c mice. Original magnification, ×200; scale bars: 100 μm. (c) Liver triglyceride levels. (d) Fatty acid content in liver. (e) ACC activity in liver. (f) Malonyl-CoA levels in liver. (g and h) Plasma glucose and plasma insulin levels, respectively. Error bars indicate the SE; n = 7 for the aP2-nSREBP-1c group, n = 6 for the ab^J/ab^J;aP2-nSREBP-1c group, and n = 3 for the ab^J/ab^J group. *P < 0.05, ab^J/ab^J;aP2-nSREBP-1c vs. aP2-nSREBP-1c mice; ^†P < 0.05, aP2-nSREBP-1c vs. ab^J/ab^J or ab^J/+; ^#P < 0.05 ab^J/ab^J;aP2-nSREBP-1c vs. ab^J/ab^J or ab^J/+.